Pharmacokinetics of contrast agents targeted to the tumor vasculature in molecular magnetic resonance imaging

Contrast Media and Molecular Imaging

Volumn 5, Issue 1, 2010, Pages 9-17

  Oostendorp, Marlies ^a,b   Douma, Kim ^a,b   Hackeng, Tilman M ^a,b   Van Zandvoort, Marc A M J ^a,b   Post, Mark J ^a,b,d   Backes, Walter H ^a,b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

cNGR; Molecular imaging; MRI; Pharmacokinetic modeling; Quantum dots; Tumor angiogenesis

Indexed keywords

ASPARAGYLGLYCYLARGININE; CONTRAST MEDIUM; MICROSOMAL AMINOPEPTIDASE; PARAMAGNETIC QUANTUM DOT; QUANTUM DOT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CELL SURFACE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; MOLECULAR MAGNETIC RESONANCE IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PLASMA HALF LIFE; PLASMA VOLUME; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TUMOR; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; HALF-LIFE; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; PEPTIDES, CYCLIC; PHOTONS; QUANTUM DOTS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77449144064     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.361     Document Type: Article

References (36)

1. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J. Magn. Reson. Imag. 2002; 16(4): 407-422.
2. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63(5): 1309-1315.
3. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007; 8(1): 63-74.
4. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998; 4(5): 623-626.
5. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, Koning GA, Griffioen AW, Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J 2005; 19(14): 2008-2010.
6. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM, Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005; 53(3): 621-627.
7. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67(4): 1555-1562.
8. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000; 44(3): 433-439.
9. Geninatti Crich S, Bussolati B, Tei L, Grange C, Esposito G, Lanzardo S, Camussi G, AimeS., Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 2006; 66(18): 9196-9201.
10. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63(18): 5838-5843.
11. Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, Lanza GM. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. Faseb J 2008; 22(12): 4179-4189.
12. Oostendorp M, Douma K, Hackeng TM, Dirksen A, Post MJ, van Zandvoort MA, Backes WH. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res 2008; 68(18): 7676-7683.
13. de Lussanet QG, Backes WH, Griffioen AW, van Engelshoven JM, Beets-Tan RG. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice. Radiology 2003; 229(2): 429-438.
14. Guccione S, Li KCP, BednarskiMD. Molecular imaging and therapy directed at the neovasculature in pathologies. IEEE Eng Med Biol Mag 2004; 23(5): 50-56.
15. Villanueva FS. Molecular images of neovascularization - art for art's sake or form with a function? Circulation 2005; 111(24): 3188-3191.
16. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279(5349): 377-380.
17. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60(3): 722-727.
18. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62(3): 867-874.
19. Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol 2006; 43(10): 1509-1518.
20. Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002; 277(49): 47891-47897.
21. Buehler A, van Zandvoort MA, Stelt BJ, Hackeng TM, Schrans-Stassen BH, Bennaghmouch A, Hofstra L, Cleutjens JP, Duijvestijn A, Smeets MB, de Kleijn DP, Post MJ, de Muinck ED. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2006; 26(12): 2681-2687.
22. Neubauer AM, Sim H, Winter PM, Caruthers SD, Williams TA, Robertson JD, Sept D, Lanza GM, Wickline SA. Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med 2008; 60(6): 1353-1361.
23. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9(6): 713-725.
24. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 2009; 42(7): 948-957.
25. 3+-based T1 agent is substantially reduced when targeted to a protein microdomain. Magn Reson Imag 2008; 26(5): 608-617.
26. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008; 112(7): 2628-2635.
27. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003; 63(11): 2723-2727.
28. Mazooz G, Mehlman T, Lai TS, Greenberg CS, Dewhirst MW, Neeman M. Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. Cancer Res 2005; 65(4): 1369-1375.
29. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009; 69(3): 1182-1189.
30. Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 1992; 40(3-4): 180-193.
31. Dirksen A, Langereis S, de Waal BFM, van Genderen MHP, Hackeng TM, Meijer EW. A supramolecular approach to multivalent target-specific MRI contrast agents for angiogenesis. Chem Commun 2005(22): 2811-2813.
32. Dirksen A, Meijer EW, Adriaens W, Hackeng TM. Strategy for the synthesis of multivalent peptide-based nonsymmetric dendrimers by native chemical ligation. Chem Commun (Camb) 2006(15): 1667-1669.
33. Peters AM, Myers MJ. Basic mathematics: compartmental analysis. In Physiological Measurements with Radionuclides in Clinical Practice. Oxford University Press: New York, 1998; 13-18.
34. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY,Mayr NA, Parker GJ, Port RE, Taylor J,Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imag 1999; 10(3): 223-232.
35. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol 2000; 12(4): 191-200.
36. Savitsky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964; 36(8): 1627-1639.